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Favorable Cardiovascular Health at Young and Middle Ages and
Dementia in Older Age—The CHA Study
Thanh-Huyen T. Vu, MD, PhD; Lihui Zhao, PhD; Lei Liu, PhD; Cuiping Schiman, PhD; Donald M. Lloyd-Jones, MD, ScM; Martha L. Daviglus,
MD, PhD; Kiang Liu, PhD; Daniel B. Garside, BS; Jeremiah Stamler, MD; James F. Fries, MD; Ya-Chen Tina Shih, PhD; Norrina B. Allen, PhD
Background-—Data are sparse on the association of cardiovascular health (CVH) in younger/middle age with the incidence of
dementia later in life.
Methods and Results-—We linked the CHA (Chicago Heart Association Detection Project in Industry) study data, assessed in 1967
to 1973, with 1991 to 2010 Medicare and National Death Index data. Favorable CVH was deﬁned as untreated systolic blood
pressure/diastolic blood pressure ≤120/≤80 mm Hg, untreated serum total cholesterol <5.18 mmol/L, not smoking, bone mass
index <25 kg/m2, and no diabetes mellitus. International Classiﬁcation of Diseases, Ninth Revision (ICD-9) codes and claims dates
were used to identify the ﬁrst dementia diagnosis. Cox models were used to estimate hazard ratios of incident dementia after age
65 years by baseline CVH status. Among 10 119 participants baseline aged 23 to 47 years, 32.4% were women, 9.2% were black,
and 7.3% had favorable baseline CVH. The incidence rate of dementia during follow-up after age 65 was 13.9%. After adjustment,
the hazard ratio for incident dementia was lowest in those with favorable baseline CVH and increased with higher risk factor burden
(P-trend<0.001). The hazards of dementia in those with baseline favorable, moderate, and 1-only high-risk factor were lower by
31%, 26%, and 20%, respectively, compared with those with ≥2 high-risk factors. The association was attenuated but remained
signiﬁcant (P-trend<0.01) when the model was further adjusted for competing risk of death. Patterns of associations were similar
for men and women, and for those with a higher and lower baseline education level.
Conclusions-—In this large population-based study, a favorable CVH proﬁle at younger age is associated with a lower risk of
dementia in older age. ( J Am Heart Assoc. 2019;8:e009730. DOI: 10.1161/JAHA.118.009730)
Key Words: aging • Alzheimer’s disease • cardiovascular disease risk factors • dementia • epidemiology
D ementia, a major neurocognitive disorder commonlycaused by Alzheimer disease and vascular disease, is
highly prevalent in the elderly. In the United States, it is
estimated that 11% of individuals aged ≥65 years, and
32% of people aged ≥85 years, suffered from dementia in
2016.1 Because of the decline in memory and other
cognitive functions, dementia signiﬁcantly diminishes an
individual’s quality of life and places a heavy burden on
family and healthcare systems.2 Therefore, preventing
dementia is critical to improving the health of the
population.
Numerous epidemiological studies have focused on identi-
fying individual risk factors for dementia. Previous research
suggests that major cardiovascular disease (CVD) risk fac-
tors are associated with a higher risk of dementia, includ-
ing hypertension,3–7 hypercholesterolemia,8,9 diabetes
mellitus,5,7,10 overweight/obesity,11,12 and smoking.7,13 How-
ever, the association of favorable cardiovascular health (CVH),
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a measure of overall risk factor burden deﬁned by favorable
levels of all major CVD risk factors, ie, low-risk in young/
middle ages, and the incidence of dementia later in life has
not been thoroughly investigated. Moreover, previous studies
examining the association between CVD risk proﬁle and
dementia did not account for the competing risk of death
before dementia diagnosis, a critical issue in studies of the
elderly whose death rate is high and affected by CVD risk
factors.14–16
We linked baseline data from the CHA (Chicago Heart
Association Detection Project in Industry) study assessed in
1967 to 1973 (for participants ages ≤65 years in 1991 and
≥67 years in 2010) with fee-for-service Medicare claims and
National Death Index data from 1991 to 2010 to examine
the association between favorable CVH proﬁle in young/
middle ages and the incidence of dementia ≥40 years of
follow-up.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Participants
The CHA Study is a prospective epidemiologic investigation of
39 665 men and women ages 18 to 74 at baseline in 1967 to
1973. The details of the CHA study have been published.17
Brieﬂy, baseline examination involved collection of demograph-
ics, smoking history, medical history, and medical treatment
data by questionnaires; measurement of height, weight, supine
blood pressure, resting ECG; and blood collection for measure-
ment of serum total cholesterol and plasma glucose.
The CHA cohort has been followed through personal
contacts, National Death Index data, and linked Medicare data
for all Medicare eligible participants starting from 1991
through 2010. The study has received periodic institutional
review board approval and a waiver of consent.
To obtain data on incidence of dementia, we included
newly Medicare-eligible participants during 1991 to 2010
participants therefore had to be ≤65 years in 1991. To
increase the likelihood that participants would have incurred
Medicare claims so that we can approximate incident
dementia, we included a 2-year washout period; ie, they had
to be aged ≥67 years in 2010.
There were 15 407 age-eligible CHA participants. We
excluded those who died before 1991 or before aged 65
years (n=1731), had missing data on baseline CVD risk factors
(n=1093), were not found in the Medicare Denominator ﬁles
(n=510), were unmatched by sex, year of birth, or social security
number (n=1379), or were enrolled in Health Maintenance
Organization plans after aged 65 (n=404). We also excluded
those who had Medicare before age 65 (n=49), as they had a
special disability or end-stage renal disease to be eligible for
Medicare. In addition, to decrease the likelihood that the
participants would have been diagnosed with dementia before
age 65 years, thosewho had any claims for dementia before age
67 were excluded (n=122). The ﬁnal study sample included
10 119 participants (6839 men and 3280 women), represent-
ing 65.7% of the original age-eligible CHA cohort (Figure S1).
Exposure and Covariates
CVH status was deﬁned based on 5 established CVD risk
factors assessed at baseline. The deﬁnition of the CVH proﬁle
is published.18,19 Brieﬂy, it included 4 categories: 1) Favor-
able, deﬁned as favorable levels of all major CVD risk factors
including untreated blood pressure, untreated serum choles-
terol, bone mass index (BMI), diabetes mellitus, and smoking; 2)
Elevated (moderate-risk), deﬁned as having 0 high-risk factors
but ≥1 unfavorable/borderline values for untreated blood
pressure, untreated cholesterol, and BMI; 3) 1 high-risk factor;
or 4) ≥2 high-risk factors (Table S1). Covariates included
baseline age, race (black, non-black), sex, educational attain-
ment (years in school), and the annual number of medical care
visits from age 65 years to the time dementia was ﬁrst
diagnosed or to the censored time.
Outcome Variables
The Medicare (fee-for service) claims data contain Interna-
tional Classiﬁcation of Diseases, Ninth Revision (ICD-9)
Clinical Perspective
What Is New?
• This study reinforces previous ﬁndings on the association of
favorable cardiovascular health in younger age and neuro-
cognitive disorder in older age with more comprehensive
analyses using data from a large population-based cohort of
both men and women with decades-long follow-up.
• It suggests that cardiovascular disease-related health out-
comes and brain health may share some common causes
and may be responsive to the same preventive strategies.
What Are the Clinical Implications?
• The ﬁnding allays a common fear that a longer lifespan may
translate into a greater vulnerability for dementia, and thus
a lower quality of life in later years, by suggesting delayed
onset of dementia for those with a low risk proﬁle.
• The ﬁnding reinforces the argument for primordial preven-
tion (ie, preventing the development of risk factors).
DOI: 10.1161/JAHA.118.009730 Journal of the American Heart Association 2


















 http://ahajournals.org by on February 7, 2019
diagnosis codes in all claim ﬁles from 1991 to 2010; they
include the Medicare Provider Analysis and Review, outpa-
tient, carrier, durable medical equipment, home health, and
hospice ﬁles. As in prior studies, we used ICD-9 codes of 290,
290.0–4, 290.8–9, 294.1, 331, 331.0–2, and 331.9 to deﬁne
all types of dementia, then subtypes of dementia.20,21 Our
primary event of interest was the ﬁrst diagnosis of dementia
in any Medicare claim, regardless of whether it was the
primary reason for the medical visit, and the outcome variable
was years from aged 65 to the ﬁrst event. It is worth noting
that, in about 50% of the cases, dementia was the primary
reason for the medical visit; and about 90% of dementia cases
were established from ICD-9 diagnoses codes in outpatient
claims. Individuals who died without a dementia diagnosis
were censored, or all-cause death, instead of being censored,
remained in the population at risk (ie, a competing event).
Individuals who survived dementia-free were censored on
December 31, 2010. Information on deaths was obtained
from National Death Index data.
Statistical Analysis
Baseline characteristics were compared across baseline CVD
risk proﬁle categories using F tests for continuous variables
and Chi-square tests for binary variables. The cumulative
incidence of dementia with death treated as a competing risk
was plotted using cumulative incidence function for each CVD
risk category.
For the main analyses, we used the procedure regression
analysis of survival data (PHREG) to ﬁt a Cox proportional
hazards model to estimate the association between CVH
proﬁle and the risk of developing dementia where individuals
who died before dementia were censored (model 1). Because
death may occur before the diagnosis of dementia in
individuals who would have developed dementia (had they
lived longer), death may be considered a competing event.
Therefore, in model 2, we take into account the potential
impact of death using Fine and Gray’s extension of the Cox
regression model.22 All hazard ratios with 95% CIs were
compared between CVH groups with the high-risk group as
the reference. Models were adjusted for baseline age, race,
sex, years of education, and the annual number of medical
care visits before dementia diagnosis or until the censored
time. We adjusted for the annual number of medical care
visits to account for potential differences in the likelihood of
dementia diagnosis because individuals with more visits may
be more likely to be diagnosed. Linear trend across the CVH
strata was also tested, with CVH status as an ordinal variable.
Proportional hazard assumptions were checked using
Martingale residuals and the Kolmogorov-type supremum
test. Standard error estimates robust to misspeciﬁcation of
the Cox was also used. We also conducted sensitivity
analyses, using interaction terms between covariates, such
as CVH status and age, race, sex, or education; age and sex,
race, or education; sex and race or education; and race and
education; and splines effects of baseline age to inquire more
ﬂexible ﬁts to the data for covariates.
Previous studies suggest that the prevalence and incidence
of Alzheimer disease vary by sex.23 Therefore, analyses were
further stratiﬁed by sex. Moreover, because the level of
education is strongly associated with dementia,24 we strat-
iﬁed models by level of education at baseline (≤12 years at
school versus otherwise). Furthermore, because stroke is
considered an important cause of cognitive impairment,25 we
used an exploratory analysis, adding into the models any
interim stroke occurring from aged 65 years to the time
dementia was ﬁrst diagnosed (or to the censored time) to
examine if having a stroke before dementia may be on the
causal pathway of the association of interest.
Finally, models substituting individual risk factors for the
combined CVH proﬁle groups were used to examine the
association of each risk factor separately with the incidence
of dementia.
The analyses used SAS statistical software (version 9.4
with SAS/STAT 14.1, SAS Institute Inc, Cary, NC); a P<0.05
was considered statistically signiﬁcant.
Results
Of 10 119 CHA participants aged 23 to 47 years at baseline,
32.4% were women, 9.2% were black, and 7.3% had a
favorable baseline proﬁle. Hypertension and smoking were
the most prevalent risk factors, while diabetes mellitus was
less common at baseline (41.3%, 40.7%, and 1.3%, respec-
tively) (Table 1). People in the favorable group tended to be
younger, female, better educated, and with the lowest average
annual number of medical care visits from age 65 years to the
ﬁrst dementia diagnosis or the censored time.
After up to 43 years of follow-up since baseline examina-
tion (up to 19 years of follow-up in Medicare after reaching
age 65 years), 13.9% of the participants developed at least 1
type of dementia. The percent of those who survived without
any dementia was highest in the favorable group (84.4%), and
lowest in the ≥2 high-risk factors group (60.3%). Conversely,
the outcomes of dementia and all-cause mortality were lowest
in the favorable group (9.6% and 6.1%, respectively), and
highest in the ≥2 high-risk factors group (16.8% and 23.0%,
respectively) (P<0.001) (Figure 1).
Figure 2 shows the unadjusted cumulative incidence of
dementia taking into account the competing risk of death.
There was a signiﬁcant difference in the dementia-free
survival rate (P<0.001) across baseline CVH groups. The
cumulative incidence of dementia was lowest in the favorable
DOI: 10.1161/JAHA.118.009730 Journal of the American Heart Association 3
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group and increased with risk factor burden. Speciﬁcally, the
hazards of dementia in those with baseline favorable,
moderate, and 1 only high-risk factor were lower by 28%,
22%, and 17%, respectively, compared with those with ≥2
high-risk factors.
Model 1 of Table 2 shows that a more favorable baseline
risk proﬁle was associated with a lower hazard of dementia
after adjusting for covariates. Compared with the ≥2 high-risk
factors group, the hazards for dementia in the 1-only high-risk
factor, moderate-risk, and favorable groups were much lower
—the hazards (95% CIs) of dementia were 0.80 (0.71–0.91),
0.74 (0.64–0.86), and 0.69 (0.54–0.89), respectively (P-
trend<0.001). The associations were attenuated when the
competing risk of death was considered (model 2) but
remained signiﬁcant with P-trends <0.01. There was no
evidence that the proportional hazards assumption was
violated as the Kolmogorov-type supremum test results based
on 1000 simulations for all the covariates were not signiﬁcant
at alpha level=0.05 (all P>0.05). The standard error estimates
robust to misspeciﬁcation of the Cox model were similar to
the model-based counterparts, ie, the main model—the ratios
of the robust estimates of the standard error relative to the
corresponding model-based estimates for all variables ranged
from 0.98 to 1.
In the sensitivity analyses, using interaction terms between
covariates did not improve the ﬁt of the model (P=0.916 for
the likelihood ratio test). Moreover, the parameter estimates
from the model with spline effects of baseline age were
similar with the estimates from the model with baseline age
as continuous variable and spline effects were not signiﬁcant;
and the Akaike information criterion of the model with spline
effects (Akaike information criterion =23 123.627) was
Table 1. Characteristics of the Study Sample for All and by Baseline Cardiovascular Health Status
Characteristics* All
Baseline Cardiovascular Health Status
P ValuekFavorable† Moderate-Risk‡ 1 High-Risk Factor§ ≥2 High-Risk Factor§
People, n 10 119 742 2238 4220 2919
Baseline characteristics (1967–1973)
Age, y 35.3 (5.5) 33.9 (5.4) 35.2 (5.4) 35.2 (5.6) 35.9 (5.5) <0.001
Female, % 32.4 59.6 32.5 33.8 23.5 <0.001
Black, % 9.2 8.4 7.2 9.6 10.4 <0.001
Education, y 13.6 (2.6) 14.1 (2.5) 14.1 (2.7) 13.6 (2.6) 13.1 (2.6) <0.001
Smoking status, % 
Never smoker 33.1 63.3 57.9 28.5 12.9
Former smoker 25.7 36.7 42.1 23.6 13.9
Current smoker 41.3 0.0 0.0 47.9 74.0
BMI, kg/m2 25.6 (3.9) 22.1 (2.0) 25.0 (2.7) 25.0 (3.4) 27.8 (4.5) 
BMI ≥30 kg/m2, % 11.4 0 0 5.5 31.5 
SBP, mm Hg 131.8 (15.9) 114.4 (6.2) 124.0 (8.2) 131.2 (15.3) 142.9 (15.0) 
DBP, mm Hg 78.3 (10.6) 69.8 (7.4) 74.2 (7.4) 77.8 (10.3) 84.3 (10.6) 
Hypertension,§ % 40.7 0 0 40.4 82.8 
Serum cholesterol, mmol/L¶ 196.7 (35.5) 168.5 (19.9) 190.6 (27.1) 192.5 (31.5) 214.6 (41.3) 
Hypercholesterolemia,§ % 11.5 0 0 5.5 31.9 
Diabetes mellitus, % 1.3 0 0 0.8 3.3 
Annual medical care visits# 13.2 (12.4) 11.4 (10.9) 11.9 (10.8) 13.0 (12.1) 15.0 (14.0) <0.001
BMI indicates body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
*Numbers are mean (SD) unless otherwise indicated.
†Favorable level of all major CVD risk factors (BP ≤120/≤80 mm Hg and no antihypertensive medication, serum cholesterol <5.18 mmol/L and no lipid-lowering medication, not smoking,
BMI <25 kg/m2, no diabetes mellitus).
‡One or more unfavorable/borderline levels of untreated systolic blood pressure 121 to 139 mm Hg or diastolic blood pressure 81 to 89 mm Hg, or untreated serum total cholesterol
5.18 to 6.21 mmol/L, or BMI 25.0 to 29.9 kg/m2, not smoking, no diabetes mellitus.
§High-risk factors: hypertension (systolic blood pressure/diastolic blood pressure (≥140/90) or using antihypertensive medication), hypercholesterolemia (serum total cholesterol
≥6.22 mmol/L or using lipid-lowering medication), smoking, BMI ≥30.0 kg/m2, diabetes mellitus.
kP values for overall group comparisons based on Chi-square or F-test except for cardiovascular health components.
¶Divide by 0.0259 to convert to mg/dL.
#Annual number of medical care visits from age 65 years to the ﬁrst time that dementia was diagnosed or to the censored time.
DOI: 10.1161/JAHA.118.009730 Journal of the American Heart Association 4
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slightly bigger than the Akaike information criterion obtained
in the model without spline function of age (Akaike informa-
tion criterion =23 120.359).
In analyses of individual risk factors (Table S2), in model 1,
baseline blood pressure and smoking status were important
predictors of the hazards of dementia. For example, compared
with current smokers, the hazards (95% CI) for dementia in
those who were not smokers and former smokers were 0.88
(0.78–0.99) and 0.82 (0.71–0.93), respectively. When death
before dementia was considered as a competing risk (model
2), the associations of baseline smoking status to dementia
were no longer signiﬁcant. The association of baseline blood
pressure with dementia was slightly attenuated but remained
signiﬁcant; eg, in model 1, the hazards (95% CI) of dementia in
those with a favorable blood pressure level was 0.85 (0.75,
0.98), compared with those with a high-risk level, and it was
0.87 (0.76–0.99) in model 2.
In sex-speciﬁc analyses, results in men and women were
similar to the results in the main analyses, especially for
model 1. For example, in men, compared with the ≥2 high-risk
factors group, the hazards (95% CIs) of dementia in the
baseline low-risk, moderate-risk, and 1-only high-risk factor
groups were 0.62 (0.40–0.97), 0.80 (0.67–0.96), and 0.83
(0.72–0.97), respectively; and, in women, they were 0.68
(0.49–0.94), 0.63 (0.49–0.82), and 0.74 (0.60–0.92), respec-
tively (Table S3). The interaction terms for sex and CVH proﬁle
in both models, were not statistically signiﬁcant (P>0.05).
In the analysis stratiﬁed by education level, results were
also similar in both the low (≤12 years of schooling) and high
(>12 years of schooling) baseline education groups, espe-
cially in model 1, in that the better the CVH status at younger
age, the lower the likelihood of having dementia later in life
with P-trends <0.05 (Table S4). The interaction terms for the
dichotomized education level and CVH proﬁle in both models
were not statistically signiﬁcant (P>0.05).
In the analysis with an additional adjustment for any
interim stroke before dementia, the association of CVH status
and dementia remained strong, although the interim stroke
slightly attenuated the association for vascular dementia. For
example: in model 1 without adjustment for an interim stroke,
the hazards for all types of dementia (95% CI) in the favorable





























Figure 1. Dementia status and death before dementia during 1991 to 2010 by baseline cardiovascular
health status. Death before dementia: all-cause death before the ﬁrst diagnosis of any type of dementia.
Favorable level of all major cardiovascular disease risk factors (blood pressure ≤120/≤80 mm Hg and no
antihypertensive medication, serum cholesterol <5.18 mmol/L and no lipid-lowering medication, not
smoking, bone mass index <25 kg/m2, no diabetes mellitus); Moderate-risk: One or more unfavorable/
borderline levels of untreated systolic blood pressure 121 to 139 mm Hg or diastolic blood pressure 81 to
89 mm Hg, or untreated serum total cholesterol 5.18 to 6.21 mmol/L, or BMI 25.0 to 29.9 kg/m2, not
smoking, no diabetes mellitus; High-Risk: High systolic blood pressure/diastolic blood pressure (≥140/90)
or using antihypertensive medication, serum total cholesterol ≥6.22 mmol/L or using lipid-lowering
medication, smoking, bone mass index ≥30.0 kg/m2, diabetes mellitus. CVH indicates cardiovascular
health. *P value for group comparison based on Chi-square tests.
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group, and with additional adjustment for interim stroke, it
was 0.70 (0.54–0.90). The hazards for vascular dementia
(95% CI) without adjustment for the interim stroke was 0.46
(0.31–0.69), and it was 0.51 (0.34–0.76) with adjustment for
the interim stroke (Table S5).
Discussion
In this study of 6839 men and 3280 women aged 23 to 47
years at baseline, we found that after up to 43 years of follow-
up since baseline examination (with 19 years follow-up in
Medicare after reaching age 65 years), a favorable CVH proﬁle
at young/middle ages was associated with 30% lower risk of
developing dementia later in life compared with those with ≥2
high-risk factors. This lower risk was independent of baseline
age, sex, race, education, and annual medical care visits
before dementia diagnosis, and it increased in a graded
fashion with burden of cardiovascular risk factors. With death
free of dementia as a competing risk, the association was
attenuated but remained signiﬁcant. The associations were
similar for men and women, and for those with a higher and
lower baseline education level; they were mainly driven by
baseline smoking and blood pressure levels.
Previous epidemiological studies have highlighted strong
associations of the combined effects of favorable levels of
all major CVD factors in young adulthood and middle age
on subsequent health outcomes including CVD mortality
and morbidity,26–29 subclinical atherosclerosis and markers
of inﬂammation.30–32 The beneﬁts of favorable CVH have
been seen for non-CVD outcomes including lower risk of
cancer33 and general functional disability,18 better quality of
life,19,34 and lower healthcare costs.29 Few longitudinal
studies have addressed the association of the combined
effect of CVD risk factors on cognitive function35,36 and
dementia;37–40 our ﬁndings are consistent with results of
these studies. For example, the Northern Manhattan Study
found that among 1033 middle-aged participants, those
with a higher number of ideal CVH metrics at baseline
(including the 5 factors considered here plus diet and
physical activity) experienced smaller decline in cognitive
performance during 6-year follow-up in older age (mean age
at initial cognitive measurement 72 years).35 This study
focused on a subgroup of survivors of the original study,
hence the results may not be generalizable to the full study
population.
The Young Finns Study, which followed children aged 3 to
18 years at baseline for 31 years, found that the number of
CVD risk factors measured in childhood was inversely
associated with midlife cognitive performance.36 The Three-































Demena-Free Survival Time Aer Age 65 (Years)
Figure 2. Cumulative incidence of dementia after aged 65 years during 1991 to 2010 by baseline
cardiovascular health status. First diagnosis of any type of dementia. Favorable level of all major
cardiovascular disease risk factors (blood pressure ≤120/≤80 mm Hg and no antihypertensive medication,
serum cholesterol <5.18 mmol/L and no lipid-lowering medication, not smoking, bone mass index <25 kg/
m2, no diabetes mellitus); Moderate-risk: One or more unfavorable/borderline levels of untreated systolic
blood pressure 121 to 139 mm Hg or diastolic blood pressure 81 to 89 mm Hg, or untreated serum total
cholesterol 5.18 to 6.21 mmol/L, or bone mass index 25.0 to 29.9 kg/m2, not smoking, no diabetes
mellitus; High-risk: high systolic blood pressure/diastolic blood pressure (≥140/90) or using antihyper-
tensive medication, serum total cholesterol ≥6.22 mmol/L or using lipid-lowering medication, smoking,
bone mass index ≥30.0 kg/m2, diabetes mellitus. *P value for the Wald test.
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(mean age at baseline 74 years) among survivors who
participated in the follow-up test, found a lower hazard for
dementia was associated with an increased number of
optimal CVH factors.40 Other studies focused on dementia
as the outcome but did not examine the combined effects of
favorable levels of all risk factors earlier in life, examining
instead only the effects of individual risk factors7 and/or
using only standard Cox regression models.37–39 These other
studies also focused only on men of the same age39 or
measured risk factors at older age.38
To our knowledge, this study is the ﬁrst American
population-based study to report that having a favorable
CVH proﬁle earlier in life is associated with lower incidence of
dementia later in life, considering death before dementia as a
competing risk in the analyses. Because of our large sample
size and rich information on diagnoses from Medicare claims,
we were able to examine the association not only for the
whole cohort, but also in men and women, and for high and
low education levels separately.
Our results on the associations of CVD risk factors
assessed singly with the risk of dementia were also consistent
with data previously published. We found baseline smoking
status and blood pressure levels were all signiﬁcantly
associated with the risk of dementia.5,6,8–10,12,13 We also
found an association between smoking status and dementia
was affected by the competing risk of death;7 these are
probably because of the high competing outcome of death in
smokers and deaths (eg, by stroke) in hypertensive people is
high.14,41
Our study beneﬁted from the use of data from a large
population-based cohort of >10 000 individuals, including
both men and women. Also, all CVD risk factors were
measured objectively >40 years ago when all the partici-
pants were at young/middle ages. Furthermore, the com-
bination of CVD risk data with data from the National Death
Index and 19 years of Medicare claims allowed us to assess
the 4-decade-long association of baseline CVD risk proﬁle
and the cumulative incidence of dementia during older ages,
considering the competing risk of death before dementia
diagnosis.
Despite the strengths, the study has limitations. First,
early and sustained drug therapy and changes in lifestyle
may modify decades-long CVD risks, thereby inﬂuencing the
association of early CVD risk proﬁle and dementia later in
life—an issue we are unable to address in this study.
Nonetheless, just a single ascertainment of the favorable
CVD risk status at younger age highlights its important role
not only for CVD but also non-CVD related outcomes in this
and other population-based studies.18,26,27,29,42 Second, our
analyses included only participants who enrolled in fee-for-
service Medicare. However, CVH was not related to fee-for-
service versus HMO enrollment. Third, the use of ICD-9
diagnosis codes in Medicare claims only may lead to an
imprecise estimate of actual dementia cases. However,
administrative data generally are concordant with patient
chart data in recording comorbidity (agreement >85%).43
Administrative data were found to be sensitive and speciﬁc
for identifying older adults with Alzheimer and related
dementias.44 Using Medicare claims to identify all types of
dementia had a sensitivity of 85% and speciﬁcity of 89%
compared with in-home dementia assessment by
clinicians.20 Medicare data have been used to estimate
national prevalence of all types of dementia and the
subtypes.45 Moreover, any possible misclassiﬁcation on
identifying dementia using Medicare data would be similar
across CVD risk strata (non-differential), ie, it would
underestimate the association. Fifth, information on cogni-
tive function at baseline was not available. However, CHA
participants were all employed at baseline in 1967 to 1973,
thus the proportion of poor cognitive performance at
baseline was likely low. Finally, apart from modiﬁable risk
factors, dementia also has genetic risk factors not assessed
here.
Table 2. Hazard Ratios (95% CIs) for Any Dementia* After




































CVH indicates cardiovascular health; ICD-9, International Classiﬁcation of Diseases, Ninth
Revision.
*Dementia was deﬁned as any dementia-related diagnoses with ICD-9: 290, 290.0–4,
290.8–9, 294.1, 331, 331.0–2, 331.9. Medicare claims during 1991 to 2010 (including
fee-for-service, for inpatient, outpatient [institutional and non-institutional], skilled
nursing, durable medical equipment, home health, and hospice claims).
†Ideal levels of all major cardiovascular disease RFs (systolic blood pressure /diastolic
blood pressure ≤120/≤80 mm Hg and no antihypertensive medication, serum total
cholesterol <5.18 mmol/L and no cholesterol-lowering medication, not smoking, bone
mass index <25 kg/m2, and no diabetes mellitus).
‡Borderline levels of systolic blood pressure /diastolic blood pressure or serum total
cholesterol, not smoking, bone mass index 25.0 to 29.9 kg/m2, and no diabetes
mellitus.
§High-risk factors: hypertension (systolic blood pressure /diastolic blood pressure
[≥140/90] or using antihypertensive medication), hypercholesterolemia (serum total
cholesterol ≥6.22 mmol/L or using lipid-lowering medication), smoking, bone mass
index ≥30.0 kg/m2, diabetes mellitus.
kP value for graded association across 4 baseline risk factor groups with risk factor
status as an ordinal variable.
¶Model 1: Adjusted for baseline age, sex, race, education attainment, and average
number of claims per years before dementia diagnosis.
#Model 2: Adjusted for baseline age, sex, race, education attainment, annual average
number of claims before dementia diagnosis and death before dementia diagnoses.
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Conclusion
Our ﬁndings highlight and extend the importance of having
favorable levels of all major CVD heath factors in young
adulthood and early middle age for preventing or delaying
neuro-cognitive disorder in older age. Our ﬁndings support an
understanding that CVD-related health outcomes and brain
health share common underlying protective mechanisms.46
Our study therefore not only supports the goal of improving
cardiovascular health,47 but also supports the national effort
of attaining high-quality, longer lives free of disability for
individuals and reducing burdens on families and society.48
Findings from this study also have implications on the
clinical perspective. In previous publications, we have shown
that low risk or higher CVH proﬁle is associated with longer
lifespan26,29 and delaying the onset of all-cause and CVD
morbidity.29 Yet there is a common fear that a longer lifespan
may translate into a greater vulnerability for dementia, and
thus a lower quality of life in later years. But our ﬁndings—
that at any time during follow-up, the hazard of dementia in
the low risk people is lower than in the high risk people—
together with our previous ﬁndings suggest delayed onset of
dementia for those with a low risk proﬁle, allaying some of the
fear commonly associated with a longer lifespan and bolster-
ing the argument for primordial prevention (ie, preventing the
development of risk factors).
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Table S1. Definitions of Favorable, Elevated and High Levels of Cardiovascular Health Factors. 
 
Definitions of Favorable, Elevated and High Levels of CV Health Factors 




(mm Hg ) 




Non-smoker No diabetes  < 25  Untreated  
SBP/DBP ≤ 120/80 
Untreated cholesterol < 5.18 mmol/L 
or 200 mg/dl* 
Moderate-Risk 
(Elevated) 
 -  - 25.0-29.9 Untreated SBP/DBP 
121-139/81-89  
Untreated cholesterol 5.18-
6.21mmol/L or 200-239 mg/dl 
High-Risk Smoker Diabetes ≥ 30 SBP/DBP ≥ 140/90 or 
taking antihypertensive 
medications 
Cholesterol level ≥ 6.22 mmol/l or 
240 mg/dl, or taking cholesterol-
lowering medication 
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Table S2. Hazard Ratios (95%Confidence Intervals) for Dementia* by Baseline Individual Risk Factors (1967-73). 
Baseline Individual Risk Factors Model 1† Model 2 ‡ 
Smoking Status                     Not smokers 0.88 (0.78-0.99) 0.99 (0.88-1.12) 
                                               Ever smokers 0.82 (0.71-0.93) 0.92 (0.80-1.05) 
                                               Current smokers  1.00 1.00 
BMI(kg/m2 )                           < 25 0.92 (0.77-1.09) 0.99 (0.83-1.17) 
                                                ≥25 and <30 0.89 (0.76-1.05) 0.94 (0.79-1.10) 
                                                ≥30   1.00 1.00 
BP Level/Med. Use                ≤120/80 mmHg, no meds 0.85 (0.75-0.98) 0.87 (0.76-0.99) 
                                                >120/80, ≤140/90, no meds 0.89 (0.79-1.02) 0.94 (0.83-1.07) 
                                                ≥ 140/90 or on meds  1.00 1.00 
Cholesterol Level/Meds Use: <5.18 mmol/l§, no meds 0.86 (0.74-1.01) 0.86 (0.74-1.00) 
                                                ≥5.18 and <6.22, no meds 0.96 (0.82-1.12) 0.95 (0.80-1.11) 
                                                 ≥6.22 or on meds  1.00 1.00 
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*Dementia were defined as any dementia-related diagnoses with ICD-9: 290, 290.0–4, 290.8–9, 294.1, 331, 331.0–2, 331.9. Medicare 
claims during 1991-2010 [including fee-for-service, for inpatient, outpatient (institutional and non-institutional), skilled nursing, 
durable medical equipment, home health, and hospice claims].  
† Model 1: Adjusted for baseline age, sex, race, education attainment, and annual number of medical care visits prior to dementia 
diagnosis. Deaths prior to dementia were treated as censored observations.  
‡Model 2: Adjusted for baseline age, sex, race, education attainment, and annual number of medical care visits prior to dementia 
diagnosis, taking into account the impact of deaths prior to dementia diagnosis on the association of interest.  
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Table S3. Hazard Ratios (95%Confidence Intervals) for Dementia# Age 65 During 1991-2010 by Baseline CVH Status (1967-
73), Stratified by Sex. 












 Model 1§ 0.62 (0.40-0.97) 0.80 (0.67-0.96) 0.83 (0.71-0.97) 1.0 0.002 
 Model 2|| 0.69 (0.45-1.07) 0.92 (0.76-1.10) 0.89 (0.76-1.03) 1.0 0.096 
WOMEN 
 Model 1§ 0.68 (0.49-0.94) 0.63 (0.49-0.82) 0.74 (0.60-0.92) 1.0 0.001 
 Model 2|| 0.78 (0.56-1.09) 0.73 (0.57-0.94) 0.83 (0.67-1.03) 1.0 0.037 
*Ideal levels of all major CVD RFs (SBP/DBP ≤120/≤80 mmHg and no antihypertensive medication, serum total cholesterol <5.18 
mmol/L and no cholesterol-lowering medication, not smoking, BMI < 25 kg/m2, and no diabetes). 
†Borderline levels of SBP/DBP or serum total cholesterol, not smoking, BMI 25.0-29.9 kg/m2, and no diabetes 
‡ High-risk factors: hypertension (SBP/DBP (≥ 140/90) or using antihypertensive medication), hypercholesterolemia (serum total 
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§Model 1: Adjusted for baseline age, race, education attainment, and average number of claims per years prior to dementia diagnosis.   
||Model 2: Adjusted for baseline age, race, education attainment, annual average number of claims prior to dementia diagnosis and 
death prior to dementia diagnoses. 
#Dementia were defined as any dementia-related diagnoses with ICD-9: 290, 290.0–4, 290.8–9, 294.1, 331, 331.0–2, 331.9. Medicare 
claims during 1991-2010 [including fee-for-service, for inpatient, outpatient (institutional and non-institutional), skilled nursing, 
durable medical equipment, home health, and hospice claims].  
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Table S4. Hazard Ratios (95%Confidence Intervals) for Dementia# After Age 65 During 1991-2010 by Baseline CVH Status 
(1967-73), Stratified by Education Levels. 











>12 years of schooling at baseline 
 Model 1§ 0.62 (0.43-0.90) 0.72 (0.58-0.89) 0.84 (0.69-1.01) 1.0 <0.001 
 Model 2|| 0.68 (0.47-0.99) 0.79 (0.64-0.99) 0.89 (0.74-1.07) 1.0 0.011 
 ≤12 years of schooling at baseline  
 Model 1§ 0.76 (0.54-1.08) 0.76 (0.62-0.93) 0.78 (0.66-0.91) 1.0 0.004 
 Model 2|| 0.58 (0.36-0.94) 0.79 (0.60-1.04) 0.86 (0.68-1.10) 1.0 0.016 
*Ideal levels of all major CVD RFs (SBP/DBP ≤120/≤80 mmHg and no antihypertensive medication, serum total cholesterol <5.18 
mmol/L and no cholesterol-lowering medication, not smoking, BMI < 25 kg/m2, and no diabetes). 
†Borderline levels of SBP/DBP or serum total cholesterol, not smoking, BMI 25.0-29.9 kg/m2, and no diabetes 
‡ High-risk factors: hypertension (SBP/DBP (≥ 140/90) or using antihypertensive medication), hypercholesterolemia (serum total 
cholesterol ≥ 6.22 mmol/L or using lipid-lowering medication), smoking, BMI ≥30.0 kg/m2, diabetes. 
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||Model 2: Adjusted for baseline age, race, sex, annual average number of claims prior to dementia diagnosis and death prior to 
dementia diagnoses. 
#Dementia were defined as any dementia-related diagnoses with ICD-9: 290, 290.0–4, 290.8–9, 294.1, 331, 331.0–2, 331.9. Medicare 
claims during 1991-2010 [including fee-for-service, for inpatient, outpatient (institutional and non-institutional), skilled nursing, 
durable medical equipment, home health, and hospice claims].  





 http://ahajournals.org by on February 7, 2019
Table S5. Hazard Ratios (95%Confidence Intervals) for Dementia# After Age 65 During 1991-2010 by Baseline CVH Status 
(1967-73), Further Adjusted for Interim Stroke.  











 Model 1§ 0.70 (0.54-0.90) 0.75 (0.65-0.87) 0.81 (0.72-0.92) 1.0 <.001 
 Model 2|| 0.79 (0.62-1.02) 0.87 (0.77-1.00) 0.88 (0.78-0.99) 1.0 0.020 
 
*Ideal levels of all major CVD RFs (SBP/DBP ≤120/≤80 mmHg and no antihypertensive medication, serum total cholesterol <5.18 
mmol/L and no cholesterol-lowering medication, not smoking, BMI < 25 kg/m2, and no diabetes). 
†Borderline levels of SBP/DBP or serum total cholesterol, not smoking, BMI 25.0-29.9 kg/m2, and no diabetes 
‡ High-risk factors: hypertension (SBP/DBP (≥ 140/90) or using antihypertensive medication), hypercholesterolemia (serum total 
cholesterol ≥ 6.22 mmol/L or using lipid-lowering medication), smoking, BMI ≥30.0 kg/m2, diabetes. 
§Model 1: Adjusted for baseline age, sex, race, education attainment, average number of claims per years prior to dementia diagnosis, 
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||Model 2: Adjusted for baseline age, sex, race, education attainment, annual average number of claims prior to dementia diagnosis, 
and any interim stroke occurring from age 65 to the time dementia was first diagnosed (or to the censored time), and death prior to 
dementia diagnoses. 
#Dementia were defined as any dementia-related diagnoses with ICD-9: 290, 290.0–4, 290.8–9, 294.1, 331, 331.0–2, 331.9. Medicare 
claims during 1991-2010 [including fee-for-service, for inpatient, outpatient (institutional and non-institutional), skilled nursing, 
durable medical equipment, home health, and hospice claims].  
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Figure S1. Flow Chart Depicting CHA-MEDICARE* Analysis Sample. 
                                           
*CHA, Chicago Heart Association Detection Project in Industry Study
Analysis Sample 
 (n=10,119) 
(6,839 men, 3,280 women) 
CHA participants in 1967-1973 (Baseline) 
(n=39,665) 
Medicare Data from 1991-2010 
Exclusion Criteria (n=5,288) 
• Died before 1991 or prior to
age 65 (n=1,731)
• Baseline CV risk
measures were missing
(n=1,093)
• Not found in Medicare
Denominator Files (n=510)
• Sex or year of birth do not
match between CHA data
and the Denominator File
Files (n=1,379)
• Enrolled in HMO during the
entire sample period
(n=404)
• In Medicare in the years
they were younger than 65
(n=49)
• Diagnosed with dementia
before age 67 (n=122)
CHA participants ages ≤65 years in 
1991 and ≥67 years in 2010 (to be 
newly age-eligible for Medicare 
with ≥ 2 years in Medicare during 
1991-2010 (n=15,407) 
CHA participants who 
were not age-eligible 
(n=24,258) 
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